Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serentis, a biopharmaceutical company, has started a Phase II clinical trial in pruritus associated with atopic dermatitis, a type of eczema.
Subscribe to our email newsletter
The Phase II, double blind, vehicle-controlled cross-over study is designed to determine the anti-pruritic efficacy, safety and local dermal toleration of SRD174 cream in patients with atopic dermatitis.
The study is being conducted in 12 sites in the US. Results from the trial are expected later in the autumn of 2009.
Tim Sharpington, CEO of Serentis, said: “SRD174 is an innovative product with the potential to address a significant unmet need in the treatment of dermatological conditions. The initiation of this Phase II study is an important milestone in the development of our clinical pipeline.”